Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nonprofit Foundation Engages Industry On TB Diagnostics Development

This article was originally published in The Gray Sheet

Executive Summary

The Foundation for Innovative New Diagnostics is working with the diagnostics industry to create faster, more cost-effective tests for drug-resistant tuberculosis in developing countries

You may also be interested in...



New FDA Groups For Rare, Neglected Diseases Could Speed Path To Market

Two new FDA review groups to recommend solutions for the prevention, diagnosis and treatment of rare diseases and neglected diseases of the developing world would help get treatments to market faster, patient advocates and lawmakers say

New FDA Groups For Rare, Neglected Diseases Could Speed Path To Market

Two new FDA review groups to recommend solutions for the prevention, diagnosis and treatment of rare diseases and neglected diseases of the developing world would help get treatments to market faster, patient advocates and lawmakers say

Tests Designed For Developing World Could Benefit Established Markets, Too

Test makers should view the developing world as a primary market feeding new technologies into more established economies, rather than the other way around, said speakers July 28-29 at the American Association of Clinical Chemistry annual meeting in Washington, D.C

Latest Headlines
See All
UsernamePublicRestriction

Register

MT025736

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel